Overview
Registration
Faculty
View Archive

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca and Jazz Pharmaceuticals, Inc.

Virtual Tumor Board®: Navigating Novel Emerging Therapeutic Approaches for the Management of SCLC Across Lines of Care

Virtual Tumor Board®: Navigating Novel Emerging Therapeutic Approaches for the Management of SCLC Across Lines of Care


July 15, 2020

Live Webcast! 8:00 PM - 9:30 PM ET

Overview

After several decades, new standards of therapy are being established for patients with small cell lung cancer (SCLC). These include immune checkpoint inhibitors in both newly diagnosed and previously treated patients, as well as inhibitors of oncogenic transcription in platinum-pretreated patients. Given the rapid therapeutic development in SCLC, it is important for physicians to be up-to-date on the optimal application of agents with novel mechanisms of action in order to optimize outcomes for their patients.

This live webcast will be presented by experts in SCLC and will begin with a rapid overview of clinical data leading to recent approvals, as well as emerging approaches and management of treatment-related adverse events. The heart of this program includes several case-based tumor board discussions addressing the application of new agents in a variety of clinical settings in SCLC. This program will also allow you to submit questions to the expert panel, providing you with additional confidence in applying new data to the care of your patients with SCLC.

Benefits of Attending

  • Hear expert opinions on the latest clinical data on new standards of care for patients with SCLC
  • Gain expert perspectives through expert-led tumor board discussions
  • Integrate newly available agents to improve outcomes in your patients with SCLC
  • Learn about optimizing safety with new therapeutic approaches in SCLC

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca and Jazz Pharmaceuticals, Inc.

Target Audience

This educational activity is directed toward medical oncologists and radiation oncologists involved in the treatment and management of patients with lung cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lung cancer may also participate.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Apply new standards of care for patients with newly diagnosed and relapsed/refractory SCLC
  • Assess strategies to mitigate and manage treatment-related adverse events in patients with SCLC
  • Evaluate novel agents and approaches for patients with extensive-stage and limited-stage SCLC
  • Discuss the status of techniques to select patients and optimize therapy among patients with SCLC

Hot Topics

  • Recently approved agents in SCLC, including immunotherapy and inhibitors of oncogenic transcription
  • Mitigation and management of treatment-related adverse events
  • Case-based tumor board discussions in multiple clinical scenarios in SCLC



Register

You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information


Registration Information


Professional Information


Specialties*

Submit
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
262728293031
Filter By